Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
